Technical Analysis for XRTX - Xortx Therapeutics Inc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing High | Bullish | 3.80% | |
| 180 Bullish Setup | Bullish Swing Setup | 3.80% | |
| Wide Bands | Range Expansion | 3.80% | |
| Overbought Stochastic | Strength | 3.80% | |
| Narrow Range Bar | Range Contraction | 10.81% | |
| Wide Bands | Range Expansion | 10.81% | |
| Overbought Stochastic | Strength | 10.81% | |
| Wide Bands | Range Expansion | 9.33% | |
| Overbought Stochastic | Strength | 9.33% | |
| 1,2,3 Pullback Bullish | Bullish Swing Setup | 13.89% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Bullish 180 Entry | 22 minutes ago |
| Rose Above Previous Day's High | 22 minutes ago |
| Up 3% | 22 minutes ago |
| Up 2% | 22 minutes ago |
| Up 1% | 22 minutes ago |
Get this analysis on your stocks daily!
- Earnings date: 2023-11-10
Xortx Therapeutics Inc Description
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, hypertension, insulin resistance, and diabetic nephropathy. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is headquartered in Vancouver, Canada.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medical Specialties Diabetes Organ Systems Infection Hypertension Kidney Disease
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 4.25 |
| 52 Week Low | 0.33 |
| Average Volume | 37,251 |
| 200-Day Moving Average | 0.947 |
| 50-Day Moving Average | 1.236 |
| 20-Day Moving Average | 2.192 |
| 10-Day Moving Average | 3.612 |
| Average True Range | 0.341 |
| RSI (14) | 78.49 |
| ADX | 49.29 |
| +DI | 54.730 |
| -DI | 7.476 |
| Chandelier Exit (Long, 3 ATRs) | 3.228 |
| Chandelier Exit (Short, 3 ATRs) | 1.392 |
| Upper Bollinger Bands | 5.348 |
| Lower Bollinger Band | -0.965 |
| Percent B (%b) | 0.78 |
| BandWidth | 288.037 |
| MACD Line | 0.870 |
| MACD Signal Line | 0.719 |
| MACD Histogram | 0.151 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.355 | ||||
| Resistance 3 (R3) | 4.317 | 4.143 | 4.288 | ||
| Resistance 2 (R2) | 4.143 | 4.040 | 4.163 | 4.265 | |
| Resistance 1 (R1) | 4.047 | 3.976 | 4.095 | 4.085 | 4.242 |
| Pivot Point | 3.873 | 3.873 | 3.898 | 3.893 | 3.873 |
| Support 1 (S1) | 3.777 | 3.770 | 3.825 | 3.815 | 3.658 |
| Support 2 (S2) | 3.603 | 3.706 | 3.623 | 3.635 | |
| Support 3 (S3) | 3.507 | 3.603 | 3.613 | ||
| Support 4 (S4) | 3.545 |
